Study objectives-The aims were (1) to compare discharge diagnoses and concurrent medication in a pharmacy based cohort of users of H2 receptor antagonists to those in a population of users of other drugs in the same period, who did not use H2 receptor antagonists; (2) to compare these results to those of a similar study performed with the Tayside record linkage scheme.
retrospective cohort study. The morbidity data from the only hospital in one medium sized city (62 000 inhabitants) were linked to the dispensing data of all five community pharmacies on an individual basis (April 1, 1986-December 31, 1989). In the absence of a unique patient identification number, data from pharmacies and hospital were linked by the combination of date of birth, gender, and general practitioner code. For every user ofH2 receptor antagonists two controls were obtained from all patients who had not used these drugs, and matched for age (within 5 years), gender, and general practitioner. All discharge diagnoses which followed this first prescription up to December 31, 1989 , in a patient in the index cohort, and during the same period in his or her matched controls, were included in the study.
Main results-In the index cohort (n = 2174) 341 persons were admitted (526 admissions) as against 398 persons (527 admissions) in the control cohort (n = 4348). There was increased morbidity in the index cohort, especially concerning the gastrointestinal system (peptic ulcers and malignancies, abdominal pain, gastrointestinal haemorrhage), but also concerning the musculoskeletal, respiratory, and circulatory systems. The morbidity in the last three groups corresponded with drugs used concomitantly by patients in the index cohort, so it was probably not causally related to the intake of H2 receptor antagonists but was rather an indicator of higher levels of morbidity in the index cohort. had not been recorded. Because two controls were matched with each index patient the control cohort had twice as much person-year experience as the index cohort. The average person-year experience in both cohorts was 1-61 year. The mean age in both the index (n = 2174) and control (n = 4348) cohorts was 60 years. In both cohorts 53 % of patients were female. The total number of prescriptions in the index group was 59 668 (27-5 prescriptions/patient) as against 63 173 (14 5 prescriptions/patient) in the control group.
Conclusions

ADMISSIONS
A total of 6635 patients who had used one or more prescriptions was admitted to the hospital, thus representing 10-7% of the city population (n = 62 000). In the index cohort 341 out of 2174 patients (1577%) had been admitted once or several times (total number of admissions: 526) during the study period, whereas the 398 control patients (9-2%) accounted for a total of 527 admissions. The admission rate in the index cohort was 1/6.5 person-years as against an admission rate in the control cohort of 1/13.1 person-years. The admission rate ratio in index versus control cohort was calculated at 2-0 (950o (table I) . Discharge diagnoses in index and control groups in this study are compared to those of the Tayside system in table II. Increased morbidity concerning diseases of the digestive system was present in the index cohorts in both systems but increased morbidity was also noted in other disease categories, such as neoplasms, and diseases of the musculoskeletal, circulatory and respiratory systems. No significantly increased morbidity was seen in our study for diseases of the skin, genitourinary, and central nervous systems. Table III represents a more detailed analysis of discharge diagnoses of the digestive system. Besides the expected increase in the numbers of index patients with peptic and duodenal disease, gastrointestinal haemorrhage, and abdominal pain, there was also a substantial increase in the discharge diagnoses concerning the gallbladder and biliary tract and hiatus hernia. The number of cancers of the oesophagus and stomach was relatively high. antianaemic preparations (B03), diuretics (C03), systemic antibiotics (JO 1), anti-inflammatory and antirheumatic products (MO1), analgesics (N02), psycholeptics (N05), and cough and cold preparations (R05) was also increased compared to controls.
Discussion
In this feasibility study there was a significantly increased rate ratio of admissions in the cohort of patients treated with H2 receptor antagonists as compared to the control cohort. This increase was partly explained by an enhanced number of discharge diagnoses of gastrointestinal problems, but in addition the number of discharge diagnoses related to morbidity in several other bodily systems was also increased. Three types of morbidity could be distinguished in the index cohort. Firstly, there was the morbidity or comorbidity due to peptic complications, which may be directly related to the reason for use of H2 receptor antagonists, eg, peptic ulcers, abdominal pain, or dyspepsia. The increase of diagnoses concerning the gallbladder and biliary tract, as seen in both the Tayside scheme and in our study, is possibly explained by those cases in which the initial symptoms were wrongly attributed to peptic ulcer disease. Similarly, some of the cases of gastrointestinal malignancy may be due to misjudgment of symptoms. Secondly, some discharge diagnoses may be related to adverse effects of H2 receptor antagonists. These may be difficult to detect since the incidence of adverse effects due to these drugs as a cause for hospital admission is probably low. Large record linkage systems and a well chosen research hypothesis are essential to identify and quantify these effects. Thirdly, there is the unexplained increase in admissions due to morbidity in other systems. The complex morbidity pattern in users of H2 receptor antagonists has also been noted in other studies. 1 5 As drugs are prescribed to treat prevailing morbidity, concurrent drug use is an indicator for (co-)morbidity. It is obvious from table IV (column VI) that most ATC groups were used more frequently in the index than the control cohort. This is consistent with the higher overall number of prescriptions used in the index cohort. This strongly suggests that the prevalence of morbidity in the index cohort was higher than in the control cohort. Interestingly, in the hospital inpatient group (table IV, column II) the increase in disorders of the gastrointestinal, musculoskeletal, respiratory, and circulatory systems was compatible with the significantly increased use of gastrointestinal antispasmodics and anticholinergics (A03), antiemetics and antinauseants (A04), laxatives (A06), vitamins (Al 1), antianaemic preparations (B03), diuretics (C03), anti-inflammatory and antirheumatic products (MO 1), analgesics (N02), and cough and cold preparations (R05). It is unlikely that these effects reflect adverse effects to H2 receptor antagonists. More likely, these drugs are relatively frequently used in patients with other illnesses and not causally related to these diseases.
The design of this feasibility study was largely similar to that performed with the Tayside record linkage system,'0 11 but there were some differences. Firstly, because of the smaller population we made our study period longer. Secondly, at the moment of performing the Tayside study, cimetidine was the only agent marketed in the United Kingdom. Despite the fact that more H2 receptor antagonists were involved in our study, however, the results were remarkably similar. There was, however, in both index and control patients a much lower overall admission rate in this study than in the Tayside study. It is uncertain whether this is due to a variation in regional and/or national morbidity patterns, health care service, or both. Although the admission rate ratios in both studie. were comparable, the ratios in our study were consistently lower. Also the relative risk for diseases of the digestive system is of lower magnitude in our study. There are three possible explanations for this difference. Firstly, and most likely, our study was performed 10 years after the introduction of H2 receptor antagonists on the market in a phase when these agents are increasingly used for all kinds of dyspeptic complaints and abdominal pain. '6 In the Tayside study cimetidine had been introduced fairly recently, and it is likely that at that time its use was more rigorously restricted to patients with demonstrated peptic ulcer disease. This is compatible with the much lower overall percentage of users of H2 receptor antagonists in the Tayside study. Obviously, as regards peptic ulcer related admissions, this would lead to a relative risk ofhigher magnitude. Secondly, in the Tayside study community based controls were enrolled. The use of community based controls would inflate the relative risk estimation if the control has died or moved to another area. In our study each control patient had had a prescription in the study period. This guaranteed that both index and control patients were eligible for medical services, and thus were alive and present in the area. Thirdly, one might argue that pharmacy based controls are generally more ill than community based controls, which would ultimately lead to more admissions. This is, however, not a likely explanation since over a three year period more than 900, of the population obtains one or more prescriptions (Herings R M C, unpublished data). This means that a randomly chosen pharmacy based control is probably representative of the total city population. Moreover, the much lower overall admission rate in the controls in our study than in those of the Tayside study is not consistent with higher morbidity.
The PHARMO system has some advantages. Although probabilistic linkage seems to be a disadvantage because of potential misclassification, this is not a great problem with a specificity of 9600. Moreover, misclassification will be non-differential and does not influence the rate ratio of cohort studies because it will occur to the same extent in the index and control cohort. 17 Although the use of a unique patient identification number makes linking more simple, the confidentiality of such numbers has raised public and political discussions.6 Moreover large indentification numbers are difficult to recall for the average individual, and hence such numbers are not consistently used.5 In the Tayside study no NHS number was found in 24% of prescriptions."0 In our study only the absence of gender and date of birth makes linking impossible, and so the percentage that could not be linked (approximately 7%) was much smaller.
Another advantage of our system is that all drug data are automated and that, in contrast to the Tayside scheme, no manual extraction and coding of prescriptions is needed. As the collection of drug data is an integral part of the administrative procedures in automated pharmacies in The Netherlands-unlike the Tayside scheme-we have data on all other drugs dispensed to the index and control patients in the same period. This facilitates a further assessment of the concurrent morbidity in these patients. In the Tayside study, for instance, the increase in disease categories concerning the respiratory system led to speculation as regards smoking habits. Although the increased use of respiratory drugs could be compatible with this hypothesis, it could also be explained by underlying respiratory diseases. Another advantage of the availability of dispensing data is the recognition of other drug risk factors, drug-drug interactions, and detection of potential confounding variables. 18 At this moment our scheme is much smaller than the Tayside scheme, but it is currently expanded to a population of 250 000 individuals.
In conclusion probabilistic linkage with dispensing data from pharmacies and morbidity data from hospitals facilitates the performance of cohort studies. Similarly, with diagnoses as a starting point, case-control studies are possible. On the condition that both consumption and morbidity data are validated, this scheme could be a useful resource for the performance of postmarketing surveillance studies.
